End-of-day quote
Other stock markets
|
||
- GBX | - |
08/05 | UBS raises Centrica to 'buy' from 'neutral | AN |
07/05 | AstraZeneca target raised; Antofagasta lowered | AN |
Sales 2024 * | 3.89B 4.92B 409B | Sales 2025 * | 4.27B 5.4B 449B | Capitalization | 4B 5.06B 422B |
---|---|---|---|---|---|
Net income 2024 * | 470M 594M 49.48B | Net income 2025 * | 505M 638M 53.16B | EV / Sales 2024 * | 1.03 x |
Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 0.94 x |
P/E ratio 2024 * |
8.57
x | P/E ratio 2025 * |
7.87
x | Employees | - |
Yield 2024 * |
2.78% | Yield 2025 * |
3.07% | Free-Float | 92.33% |
Latest transcript on Hiscox Ltd
Managers | Title | Age | Since |
---|---|---|---|
Hamayou Hussain
CEO | Chief Executive Officer | 51 | 22/16/22 |
Paul Cooper
DFI | Director of Finance/CFO | 52 | 12/22/12 |
Stéphane Flaquet
COO | Chief Operating Officer | - | 01/10/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 60 | 16/17/16 | |
Anne MacDonald
BRD | Director/Board Member | 68 | 20/15/20 |
Colin Keogh
BRD | Director/Board Member | 69 | 19/15/19 |
1st Jan change | Capi. | |
---|---|---|
+39.59% | 62.16B | |
+16.18% | 52.72B | |
+13.28% | 49.83B | |
+19.49% | 44.62B | |
+31.67% | 36.61B | |
+11.55% | 29.51B | |
+49.51% | 28.42B | |
+27.29% | 25.57B | |
+15.79% | 21.39B |